Literature DB >> 12095472

Functional Heartburn.

Jan Tack1, Jozef Janssens.   

Abstract

Functional heartburn is defined as the presence of a retrosternal burning sensation in the absence of pathologic gastroesophageal reflux. The underlying pathophysiology seems to be heterogeneous. In a subset of patients, esophageal hypersensitivity to physiologic esophageal acid exposure is involved, and this is likely to respond to intensive antireflux treatment. Antireflux surgery was not studied systematically in these patients and should be considered only in exceptional cases. In the remaining patients, non-acid reflux, esophageal mechanosensitivity, and psychological factors may be involved. Treatment options in these patients are limited owing to a lack of studies. Emerging therapies include selective serotonin reuptake inhibitors and relaxation therapy.

Entities:  

Year:  2002        PMID: 12095472     DOI: 10.1007/s11938-002-0047-5

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  59 in total

1.  Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.

Authors:  M F Vela; L Camacho-Lobato; R Srinivasan; R Tutuian; P O Katz; D O Castell
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

2.  Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.

Authors:  R Carlsson; J Dent; R Watts; S Riley; R Sheikh; J Hatlebakk; K Haug; G de Groot; A van Oudvorst; A Dalväg; O Junghard; I Wiklund
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-02       Impact factor: 2.566

3.  Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease.

Authors:  J L Smith; A R Opekun; E Larkai; D Y Graham
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

4.  Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.

Authors:  J P Galmiche; P Barthelemy; B Hamelin
Journal:  Aliment Pharmacol Ther       Date:  1997-08       Impact factor: 8.171

5.  Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.

Authors:  J E Richter; D R Campbell; P J Kahrilas; B Huang; C Fludas
Journal:  Arch Intern Med       Date:  2000-06-26

6.  Gastroesophageal reflux: diagnosis and treatment.

Authors:  W S Battle; L M Nyhus; C T Bombeck
Journal:  Ann Surg       Date:  1973-05       Impact factor: 12.969

7.  Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors.

Authors:  B T Johnston; S A Lewis; J S Collins; R J McFarland; A H Love
Journal:  Scand J Gastroenterol       Date:  1995-01       Impact factor: 2.423

8.  Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study.

Authors:  D Broekaert; B Fischler; D Sifrim; J Janssens; J Tack
Journal:  Aliment Pharmacol Ther       Date:  2006-02-01       Impact factor: 8.171

9.  Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.

Authors:  T L Venables; R D Newland; A C Patel; J Hole; C Wilcock; M L Turbitt
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

10.  Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both?

Authors:  J Tack; G Koek; I Demedts; D Sifrim; J Janssens
Journal:  Am J Gastroenterol       Date:  2004-06       Impact factor: 10.864

View more
  1 in total

Review 1.  Current perspectives on the diagnosis and treatment of functional esophageal disorders.

Authors:  Roy Dekel; Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2003-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.